Danny Sullivan

About

Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.
68 POSTS

/

0 COMMENTS

Articles

Join me at my 100th birthday party in 2049!

We speak with GRG's Johnny Adams, a key contributor to the Longevity2020 online conference, about his quest for more healthy years. One of the speakers at this month’s...

Chemical screening to find hidden Longevity gems?

Start-up NemaLife evolves from platform technology to services provider to identify chemicals that have both positive and negative effects on Longevity. The use of the...

From machines to animals to humans

Exclusive with Prof Joao Pedro de Magalhaes: talking AI, indication expansion and animal models. “Will you still need me, will you still feed me, when...

Nutraceuticals to beat cognitive decline before it starts

Talking nutraceuticals and pharmaceuticals, trials, scaling-up and Singapore with the founder of Senescence Life Sciences. Singapore-based Senescence Life Sciences aims to use nutraceuticals to combat natural brain...

AI home monitoring tech wins Home of 2030 award

With things looking increasingly grim out there, some good news arrived in our inbox from one of the companies we covered recently: Kemuri takes...

Better, faster, stronger CRISPR

Cytosurge claims to be able to make CRISPR “better and faster than anybody else on single cell level” - seeking investment to evolve world’s smallest syringe...

An operating system for senior living

K4Connect aims to create a smart OS for senior living with a single interface for all technologies. Technology adoption among older adults has been consistently...

AI and machine vision addresses falls prevention

VirtuSense uses machine vision and AI to address the multi-million falls prevention market opportunity. According to the U.S. Centers for Disease Control and Prevention, falls...

Cerevance raising $60m for brain disease drug discovery

Company awaits Phase 2 trial readout for new Parkinson’s drug as part of its mission to combat brain disease. In the world of Longevity start-ups,...

Sign-up for daily news on the research, investments and technologies driving the Longevity market.

Sign-up for daily news on the research, investments and technologies driving the Longevity market.